James T Isaacs, Philip J Almeter, Aaron N Hunter, Thomas A Lyman, Stephanie P Zapata, Bradley S Henderson, Seth A Larkin, Lindsey M Long, Megan N Bossle, Smaran A Bhaktawara, Matthew F Warren, Austin M Lozier, Joshua D Melson, Savannah R Fraley, Eunice Hazzel L Relucio, Margaret A Felix, Jeffrey W Reynolds, Ryan W Naseman, Thomas L Platt, Robert A Lodder
{"title":"Assessment of Vecuronium Quality Using Near-Infrared Spectrometry.","authors":"James T Isaacs, Philip J Almeter, Aaron N Hunter, Thomas A Lyman, Stephanie P Zapata, Bradley S Henderson, Seth A Larkin, Lindsey M Long, Megan N Bossle, Smaran A Bhaktawara, Matthew F Warren, Austin M Lozier, Joshua D Melson, Savannah R Fraley, Eunice Hazzel L Relucio, Margaret A Felix, Jeffrey W Reynolds, Ryan W Naseman, Thomas L Platt, Robert A Lodder","doi":"10.6084/m9.figshare.24846285","DOIUrl":null,"url":null,"abstract":"<p><p>This study employed Fourier Transform near-infrared spectrometry to assess the quality of vecuronium bromide, a neuromuscular blocking agent. Spectral data from two lots of vecuronium were collected and analyzed using the BEST metric, principal component analysis (PCA) and other statistical techniques. The results showed that there was variability between the two lots and within each lot. Several outliers in the spectral data suggested potential differences in the chemical composition or sample condition of the vials. The outliers were identified and their spectral features were examined. A total of eight unique outliers were found in the PC space from PCs 1 to 9, so 22% of the total vials were outliers. The study findings suggest that the manufacturing process of vecuronium bromide may have been operating outside of a state of process control. Further investigation is needed to determine the source of these variations and their impact on the safety and efficacy of the drug product.</p>","PeriodicalId":72698,"journal":{"name":"Contact in context","volume":"2023 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10768930/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Contact in context","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.6084/m9.figshare.24846285","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
This study employed Fourier Transform near-infrared spectrometry to assess the quality of vecuronium bromide, a neuromuscular blocking agent. Spectral data from two lots of vecuronium were collected and analyzed using the BEST metric, principal component analysis (PCA) and other statistical techniques. The results showed that there was variability between the two lots and within each lot. Several outliers in the spectral data suggested potential differences in the chemical composition or sample condition of the vials. The outliers were identified and their spectral features were examined. A total of eight unique outliers were found in the PC space from PCs 1 to 9, so 22% of the total vials were outliers. The study findings suggest that the manufacturing process of vecuronium bromide may have been operating outside of a state of process control. Further investigation is needed to determine the source of these variations and their impact on the safety and efficacy of the drug product.
本研究采用傅立叶变换近红外光谱仪评估神经肌肉阻断剂维库溴铵的质量。研究人员收集了两批维库溴铵的光谱数据,并使用 BEST 指标、主成分分析 (PCA) 和其他统计技术对这些数据进行了分析。结果显示,两个批次之间以及每个批次内部都存在差异。光谱数据中的几个异常值表明小瓶的化学成分或样品条件可能存在差异。对这些异常值进行了识别,并检查了它们的光谱特征。在 PC 空间(PC 1 至 PC 9)中共发现 8 个独特的异常值,因此异常值占样品瓶总数的 22%。研究结果表明,维库溴铵的生产过程可能超出了过程控制的范围。需要进一步调查,以确定这些变异的来源及其对药品安全性和有效性的影响。